地榆升白片预防性治疗干扰素所致白细胞减少的临床分析

A clinical analysis of treating interferon-induced leukopenia with the Diyu Shengbai tablets

目的:观察地榆升白片预防性治疗在干扰素所致白细胞减少中的应用效果及安全性。方法:随机将2014年2月-2017年2月期间收治的28例行干扰素治疗的慢性乙型肝炎患者分为观察组(予以地榆升白片预防性治疗,n=14)和对照组(予以利可君片预防性治疗,n=14),对两组患者治疗后不同时间粒细胞、白细胞变化情况,血小板、血色素变化情况等指标进行观察和对比。结果:组间不同时间粒细胞、白细胞、血小板及血色素变化情况对比,观察组所得结果明显优于对照组,P<0.05。结论:地榆升白片在干扰素所致白细胞减少中的预防性治疗效果显著,值得推广。

Objective： To observe efficacy of the Diyu Shengbai tablets（ 地榆升白片） on interferon-induced leukopenia. Methods： From February 2014 to February 2017, 28 patients with chronic hepatitis B were divided into two groups, 14 cases in each group. The observation group was given the Diyu Shengbai tablets; and the control group was given the Li Kejun tablets（ 利可君片）. After treatment, granulocytes, white blood cell changes, platelets, hemoglobin, etc. in two groups on different times were compared. Results： Granulocytes, white blood cell changes, platelets, hemoglobin, etc. in the observation group were better, P〈0.05. Conclusions： The Diyu Shengbai tablets on interferon-induced leukopenia shows a good effect, and is worthy of promotion.